Pharmacokinetics and pharmacodynamics of arterolane maleate following multiple oral doses in adult patients with p. falciparum malaria

Journal of Clinical Pharmacology

Volumn 51, Issue 11, 2011, Pages 1519-1528

  Gautam, Anirudh ^a   Ahmed, Tausif ^a   Sharma, Pradeep ^a   Varshney, Brijesh ^a   Kothari, Monika ^a   Saha, Nilanjan ^a   Roy, Arjun ^a   Moehrle, Joerg J ^b   Paliwal, Jyoti ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

^b International Center Cointrin   (Switzerland)

Author keywords

Arterolane; malaria; P. falciparum; patients; pharmacodynamics; pharmacokinetics; recrudescence

Indexed keywords

ARTEROLANE; ARTEROLANE MALEATE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MULTICENTER STUDY; PARASITE CLEARANCE; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIMALARIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALARIA, FALCIPARUM; MALE; MALEATES; MIDDLE AGED; PEROXIDES; PLASMODIUM FALCIPARUM; SPIRO COMPOUNDS; YOUNG ADULT;

EID: 80054771436     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010385578     Document Type: Article

References (21)

1. World Health Organization. World malaria report, 2008. http://www.who.int/malaria/wmr2008/malaria2008.pdf. Accessed October 27, 2010.
2. Medicine for Malaria Venture WEB SITE. http://www.mmv.org. Accessed October 27, 2010.
3. Ridley RG. Medical need, scientific opportunity, and the drive for antimalarial drugs. Nature. 2002 ; 415: 686-693 (Pubitemid 34136402)
4. Shanks GD. Treatment of falciparum malaria in the age of drug resistance. J Postgrad Med. 2006 ; 52: 277-280 (Pubitemid 44862767)
5. VennerstromJLTangYDongY. United States Patent No. 6,825,230 B2. 2004.
6. Vennerstrom JL, Arbe-Barnes S, Brun R, et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature. 2004 ; 430: 900-904 (Pubitemid 39119218)
7. Kreidenweiss A, Mordmüller B, Krishna S, Kremsner PG. Antimalarial activity of a synthetic endoperoxide (RBx-11160/OZ277) against plasmodium falciparum isolates from Gabon. Antimicrob Agents Chemother. 2006 ; 50: 1535-1537
8. Maerki S, Brun R, Charman SA, Dorn A, Matile H, Wittlin S. In vitro assessment of the pharmacodynamic properties and the partitioning of OZ277/RBx-11160 in cultures of plasmodium falciparum. J Antimicrob Chemother. 2006 ; 58: 52-58 (Pubitemid 44294987)
9. Paliwal J. Pharmacokinetics of RBx 11160 in healthy subjects and P. falciparum patients. Abstract presented at: ASTMH 55th Annual Meeting ; Atlanta, GA ;..
10. Bloland P, Ringwald P, Snow RW Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated P. falciparum Malaria. Geneva, Switzerland: World Health Organization ; 2005 :
11. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated P. falciparum Malaria. Geneva, Switzerland: World Health Organization ; 2003 :
12. Guidance for Industry Bioanalytical Method Validation. Silver Spring, MD: US Food and Drug Administration Center for Drug Evaluation and Research ; 2001 :
13. WinNonlin Pro. Mountain View, CA: Pharsight Corporation Inc; Oct, 2008 ;
14. Valecha N, Looareesuwan S, Martensson A, et al. Arterolane, a new synthetic trioxolane for treatment of uncomplicated P. falciparum malaria: a phase II multicentric randomized dose finding clinical trial. Clin Infect Dis. 2010 ; 51: 684-691
15. Ashton M, Sy ND, Gordi T, et al. Evidence for time-dependent artemisinin kinetics in adults with uncomplicated malaria. Pharm Pharmacol Lett. 1996 ; 6: 127-130 (Pubitemid 27052976)
16. Svensson USH, Ashton M, Hai TN, et al. Artemisnin and omeprazole pharmacokinetics in healthy male subjects after repeated coadministration; omeprazole as in vivo marker for CYP3A4 and CYP2C19 activity. Exp Tox Pathol. 1996 ; 48: 393
17. Alin MH, Ashton M, Kihamia C, Mtey G, Björkman A. Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans Roy Soc Trop Med Hyg. 1996 ; 90: 61-65 (Pubitemid 26069449)
18. Hoshen MB, Na-bangchang K, Stein WD, Ginsburg H. Mathematical modeling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of "dormancy," a partial cytostatic effect of the drug, and its implication for treatment regimens. Parasitol. 2000 ; 121: 237-246
19. Hoshen MB, Stein WD, Ginsburg H. Mathematical modeling of malaria chemotherapy: combining artesunate and mefloquine. Parasitol. 2000 ; 124: 9-15 (Pubitemid 34816180)
20. Angus BJ, Thaiaporn I, Chanthapadith K, Suputtamongkol Y, White NJ. Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob Agents Chemother. 2002 ; 46: 778-782 (Pubitemid 34157663)
21. Gordi T, Huong DX, Hai TN, Nieu NT, Ashton M. Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. Antimicrob Agents Chemother. 2002 ; 46: 1026-1031 (Pubitemid 34260346)